» Articles » PMID: 23328410

Lymphatic Mapping of Mice with Systemic Lymphoproliferative Disorder: Usefulness As an Inter-lymph Node Metastasis Model of Cancer

Overview
Publisher Elsevier
Date 2013 Jan 19
PMID 23328410
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Preclinical models of lymph node (LN) metastasis are fundamental to the study and design of new techniques for the diagnosis and treatment of LN metastasis. However, the identification of LNs and lymphatic vessels (LVs) in mice is challenging with conventional imaging modalities, since the LN diameter in normal mice is 1-2 mm. Here, we describe MXH10/Mo-lpr/lpr (MXH10/Mo/lpr) inbred mice, which develop systemic swelling of LNs up to 10 mm in diameter, allowing investigation of the topography of LNs and LVs. Using a gross anatomy dissection approach, we identified 22 different LNs situated in the head and neck, limbs, thoracic and abdominal regions. Furthermore, four peripheral inter-LN vessels were found: from the subiliac LN (SiLN) to the proper axillary LN (PALN); from the parotid LN to the caudal deep cervical LN; and from the popliteal LN to both the sciatic LN and the SiLN. Metastasis to the PALN via LVs was induced by inoculating FM3A/Luc mouse mammary carcinoma cells into the SiLN. Our results demonstrate that the MXH10/Mo/lpr mouse strain is an excellent model in which to investigate lymphatic drainage and inter-LN metastasis of cancer. This paper unveils the anatomy of murine lymphatics to give new insights into the investigation of inter-LN metastasis of cancer, especially the mechanisms involved in the trafficking of cancer cells through inter-LN vessels. The results provide data that may prove very useful in the quest to develop better lymph drainage-based drug delivery systems.

Citing Articles

A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform.

Jiang Y, Sanyal M, Hussein N, Baghdasaryan A, Zhang M, Wang F Sci Adv. 2025; 11(6):eadp5539.

PMID: 39919189 PMC: 11804919. DOI: 10.1126/sciadv.adp5539.


A combination of lymphatic drug delivery of anti-CTLA-4 antibody and local radiotherapy for solid-tumor treatment.

Takagi K, Sukhbaatar A, Inaba Y, Mori S, Kodama T Cancer Sci. 2024; 115(12):4021-4033.

PMID: 39380185 PMC: 11611777. DOI: 10.1111/cas.16369.


Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia.

Mishra R, Sukhbaatar A, Mori S, Kodama T J Exp Clin Cancer Res. 2023; 42(1):132.

PMID: 37259163 PMC: 10233978. DOI: 10.1186/s13046-023-02645-w.


Drug formulation augments the therapeutic response of carboplatin administered through a lymphatic drug delivery system.

Mishra R, Sukhbaatar A, Dorai A, Mori S, Shiga K, Kodama T Cancer Sci. 2022; 114(1):259-270.

PMID: 36168838 PMC: 9807524. DOI: 10.1111/cas.15599.


Combination therapy of lymphatic drug delivery and total body irradiation in a metastatic lymph node and lung mouse model.

Sora S, Sukhbaatar A, Fukushige S, Mori S, Sakamoto M, Kodama T Cancer Sci. 2022; 114(1):227-235.

PMID: 36056924 PMC: 9807513. DOI: 10.1111/cas.15562.